BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

St.Jude Children's Research Hospital Release: H5N1 Threat Puts Human Flu Back In Spotlight


5/5/2006 10:19:16 AM

MEMPHIS, Tenn., May 4 /PRNewswire/ -- The emergence of the bird flu virus H5N1 that is currently devastating chicken flocks in many countries and threatening to unleash a worldwide epidemic among humans has trigged a renewed interest among scientists in studying influenza A viruses, according to investigators at St. Jude Children's Research Hospital.

"Over the years, influenza A viruses have been one of the most important models for studying how the immune system responds to viral infections," said Peter Doherty, Ph.D. a member of the Department of Immunology at St. Jude and co-recipient of the 1996 Nobel Prize for Medicine. Doherty is the senior author of a review article that appears in the May issue of Nature Immunology. "Further study of this virus and the immune response to it will no doubt help us prepare for this latest threat."

The first way the immune system responds to influenza A viruses is by stimulating B lymphocytes to develop into antibody-forming plasma cells, according to Doherty. "If we have the "right" antibodies in our blood as a consequence of being vaccinated we are completely protected," he said. However, the HA and NA proteins on the surface of these viruses continually mutate, keeping a step ahead of the "posse" of antibodies that seek to bring them down.

On the other hand, the CD8+ "killer" T lymphocytes, which attack and kill cells infected by the virus, take longer to respond, and the virus still replicates extensively before these cells do their job. Even before people realize they're infected, they can spread the virus.

According to the authors, the "Holy Grail" of influenza vaccines would be one that would target "universal" antigens (targets) that appear on all flu viruses and that don't readily mutate.

The other authors of the paper are Paul Thomas (Immunology, St. Jude) Richard Webby (Infectious Diseases, St. Jude) and Stephen Turner (University of Melbourne, Australia).

This work was supported in part by the National Institutes of Health, the Australian National Health and Medical Research Council, Science Technology, Innovation funds from the State of Victoria, Australia, and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fund-raising organization. For more information, please visit www.stjude.org.

St. Jude Children's Research Hospital

CONTACT: Bonnie Kourvelas, Public Relations, +1-901-495-4815, orbonnie.kourvelas@stjude.org, or Marc Kusinitz, Ph.D., ScientificCommunications, +1-901-495-5020, or marc.kusinitz@stjude.org, both of St.Jude Children's Research Hospital



Read at BioSpace.com

   
Bird Flu

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES